CA2045869A1 - Fusion proteins with immunoglobulin portions, the preparation and use thereof - Google Patents

Fusion proteins with immunoglobulin portions, the preparation and use thereof

Info

Publication number
CA2045869A1
CA2045869A1 CA002045869A CA2045869A CA2045869A1 CA 2045869 A1 CA2045869 A1 CA 2045869A1 CA 002045869 A CA002045869 A CA 002045869A CA 2045869 A CA2045869 A CA 2045869A CA 2045869 A1 CA2045869 A1 CA 2045869A1
Authority
CA
Canada
Prior art keywords
fusion proteins
preparation
immunoglobulin
immunoglobulin portions
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002045869A
Other languages
French (fr)
Other versions
CA2045869C (en
Inventor
Leander Lauffer
Patricia Oquendo
Gerd Zettlmeissl
Brian Seed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Immunex Corp
Original Assignee
Leander Lauffer
Patricia Oquendo
Gerd Zettlmeissl
Brian Seed
Behringwerke Aktiengesellschaft
The General Hospital Corporation
Immunex Corporation
Hoechst Aktiengesellschaft
Hoechst Gmbh
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leander Lauffer, Patricia Oquendo, Gerd Zettlmeissl, Brian Seed, Behringwerke Aktiengesellschaft, The General Hospital Corporation, Immunex Corporation, Hoechst Aktiengesellschaft, Hoechst Gmbh, Sanofi-Aventis Deutschland Gmbh filed Critical Leander Lauffer
Publication of CA2045869A1 publication Critical patent/CA2045869A1/en
Application granted granted Critical
Publication of CA2045869C publication Critical patent/CA2045869C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Abstract

The invention relates to genetically engineered soluble fusion proteins composed of human proteins not belonging to the immunoglobulin family, or of parts thereof, and of various portions of the constant region of immunoglobulin molecules. The functional properties of the two fusion partners are surprisingly retained in the fusion protein.
CA002045869A 1990-06-28 1991-06-27 Fusion proteins with immunoglobulin portions, the preparation and use thereof Expired - Lifetime CA2045869C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4020607.6 1990-06-28
DE4020607 1990-06-28

Publications (2)

Publication Number Publication Date
CA2045869A1 true CA2045869A1 (en) 1991-12-29
CA2045869C CA2045869C (en) 2009-01-27

Family

ID=6409260

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002045869A Expired - Lifetime CA2045869C (en) 1990-06-28 1991-06-27 Fusion proteins with immunoglobulin portions, the preparation and use thereof

Country Status (17)

Country Link
EP (3) EP0464533B1 (en)
JP (2) JPH05247094A (en)
KR (3) KR100249572B1 (en)
AT (2) ATE309376T1 (en)
AU (1) AU655421B2 (en)
CA (1) CA2045869C (en)
CY (2) CY2151B1 (en)
DE (3) DE59109269D1 (en)
DK (2) DK0464533T3 (en)
ES (2) ES2120949T4 (en)
GR (1) GR3027567T3 (en)
HK (2) HK1010216A1 (en)
IE (1) IE912256A1 (en)
LU (1) LU90592I2 (en)
NL (1) NL300009I2 (en)
PT (1) PT98113B (en)
UY (1) UY25897A1 (en)

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047538A1 (en) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US5968759A (en) * 1995-10-18 1999-10-19 Centeon Pharma Gmbh Method for the quantification of activated coagulation factor VII (FVIIa)
US6210661B1 (en) 1992-03-13 2001-04-03 Aventis Pharma Deutschland Gmbh IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, and bacterial diseases and of fungal infections
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
US6403077B1 (en) 1994-12-12 2002-06-11 Beth Israel Hospital Association Treatment regimes featuring an IL-10-containing chimeric polypeptide
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6573056B2 (en) 1995-10-18 2003-06-03 Aventis Behring Gmbh Process for purifying factor VII and activated factor VII
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6743625B2 (en) 1997-03-17 2004-06-01 Human Genome Sciences, Inc. Death domain containing receptor 5
EP1624891A2 (en) † 2003-05-06 2006-02-15 Syntonix Pharmaceuticals, Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US7064189B2 (en) 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
WO2007056352A2 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
WO2007084631A2 (en) 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7476384B2 (en) 1997-01-28 2009-01-13 Human Genome Sciences, Inc. Death domain containing receptor 4 antibody and methods
EP2025682A2 (en) 1996-08-16 2009-02-18 Human Genome Sciences, Inc. Human endokine alpha
WO2009041501A1 (en) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. Factor involved in latent infection with herpesvirus, and use thereof
EP2053125A1 (en) 2003-03-04 2009-04-29 Intercell AG Streptococcus pyogenes antigens
EP2055718A1 (en) 2005-11-11 2009-05-06 Ludwig-Maximilians-Universität München Targeting and tracing of antigens in living cells
EP2065396A1 (en) 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
US7550293B2 (en) 2002-07-19 2009-06-23 Targacept, Inc. Chimeric nicotinic receptor subunits
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
WO2010093928A2 (en) 2009-02-12 2010-08-19 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
WO2010101903A2 (en) 2009-03-03 2010-09-10 Talecris Biotherapeutics, Inc. Compositions, methods and kits for preparing plasminogen; and plasmin prepared therefrom
EP2228389A2 (en) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
EP2246417A1 (en) 2004-04-22 2010-11-03 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
EP2267006A1 (en) 2003-05-30 2010-12-29 Intercell AG Enterococcus antigens
US7862820B2 (en) 2003-05-06 2011-01-04 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP2275434A1 (en) 2006-09-15 2011-01-19 Intercell AG Borrelia antigens
EP2275435A2 (en) 2003-05-07 2011-01-19 Intercell AG Streptococcus agalactiae antigens I + II
EP2314604A2 (en) 2002-10-15 2011-04-27 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US7993643B2 (en) 2000-03-02 2011-08-09 Amgen Fremont, Inc. Uses of human monoclonal antibodies against oxidized LDL receptor
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP2479277A2 (en) 2004-07-22 2012-07-25 Five Prime Therapeutics, Inc. Compositions and methods of use for MGD-CSF in disease treatment
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
EP2639301A2 (en) 2006-06-30 2013-09-18 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2013174003A1 (en) 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
US8617863B2 (en) 2008-06-04 2013-12-31 Grifols Therapeutics Inc. Composition, method, and kit for preparing plasmin
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
US8916159B2 (en) 2007-04-02 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP3023502A1 (en) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
EP3056571A1 (en) 2004-05-18 2016-08-17 Georg Dewald Methods and kits to detect hereditary angioedema type iii
EP3072963A1 (en) 2007-10-18 2016-09-28 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US10233223B2 (en) 2006-01-27 2019-03-19 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
US11028398B2 (en) 2007-07-26 2021-06-08 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (en) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
DE4228839A1 (en) * 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
AU6942994A (en) * 1993-04-30 1994-11-21 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
DE4407386B4 (en) * 1994-03-05 2009-01-15 Dade Behring Marburg Gmbh Method for reactivation of purified membrane proteins by freezing
ATE202633T1 (en) * 1994-04-28 2001-07-15 Dade Behring Inc CALIBRATOR FOR PROTHROMBIN TIME ASSAY
AU3382595A (en) * 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
ATE238668T1 (en) * 1995-01-17 2003-05-15 Brigham & Womens Hospital RECEPTOR-SPECIFIC TRANSEPITHELIAL TRANSPORT OF IMMUNOGENS
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
EP1015477B1 (en) 1997-05-30 2010-11-10 Human Genome Sciences, Inc. 32 Human secreted proteins
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
JP2002017353A (en) * 1997-12-19 2002-01-22 Japan Tobacco Inc Method for determining denaturated ldl
ES2245085T3 (en) * 1998-01-23 2005-12-16 Immunex Corporation ACPL DNA AND POLYPEPTIDES
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
JP4486256B2 (en) 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション Biologically active peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP)
US7169567B1 (en) 1998-12-31 2007-01-30 The General Hospital Corporation Screening assay utilizing the PTH receptor
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
IL145785A0 (en) * 1999-05-07 2002-07-25 Genentech Inc Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
US6362324B1 (en) 1999-06-30 2002-03-26 Millennium Pharmaceuticals, Inc. 17867 a novel human aminopeptidase
US6369210B1 (en) 1999-06-30 2002-04-09 Millennium Pharmaceuticals, Inc. 22012, human carboxypeptidase
AU7734800A (en) 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
EP1282435A2 (en) 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
ES2549767T3 (en) 2000-05-26 2015-11-02 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
BR0113512A (en) 2000-08-25 2005-05-10 Basf Plant Science Gmbh Plant polynucleotides encoding new prenyl proteases
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
ES2674888T3 (en) 2001-06-26 2018-07-04 Amgen Inc. OPGL antibodies
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
EP2201960A1 (en) 2003-03-19 2010-06-30 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
AU2012203896B2 (en) * 2003-05-06 2014-09-25 Bioverativ Therapeutics Inc. Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
US7910544B2 (en) 2003-07-17 2011-03-22 The General Hospital Corporation Conformationally constrained parthyroid hormone (PTH) analogs
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
KR20050047030A (en) 2003-11-13 2005-05-19 한미약품 주식회사 Igg fc fragment for a drug carrier and method for the preparation thereof
EP1797096B1 (en) 2004-09-06 2011-07-27 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines as inhibitors of protein kinase b (akt)
KR20070085886A (en) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 Il-7 variants with reduced immunogenicity
AU2006235266B2 (en) 2005-04-07 2010-12-23 The Cleveland Clinic Foundation Gammaretrovirus associated with cancer
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
UA97628C2 (en) 2005-08-16 2012-03-12 Ханми Холдингз Ко., Лтд. Method For the Mass Production of Immunoglobulin Fc Region Deleted Initial Methionine Residues
EP1931384A4 (en) 2005-09-09 2010-03-10 Univ Johns Hopkins Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
WO2007124464A2 (en) 2006-04-20 2007-11-01 Becton, Dickinson And Company Thermostable proteins and methods of making and using thereof
US8143374B2 (en) 2006-08-04 2012-03-27 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
KR100888022B1 (en) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 Fusion Proteion of Imunoglobulin Fc and Human Apolipoproteina Kringle Fragment
EP2489673A3 (en) 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
CN101883782A (en) 2007-06-18 2010-11-10 英特塞尔股份公司 Chlamydia antigen
JP5711966B2 (en) 2007-08-01 2015-05-07 ザ ジェネラル ホスピタル コーポレイション Screening methods using G protein-coupled receptors and related compositions
WO2009089062A2 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders
TWI388570B (en) 2008-07-23 2013-03-11 Hanmi Science Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
LT2523688T (en) 2010-01-15 2018-03-12 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
CA2805267C (en) 2010-05-04 2019-07-30 The Brigham And Women's Hospital, Inc. Detection and treatment of fibrosis
KR101900078B1 (en) 2010-05-13 2018-09-18 더 제너럴 하스피탈 코포레이션 Parathyroid hormone analogs and uses thereof
JP5886283B2 (en) 2010-07-15 2016-03-16 アドヘロン セラピューティクス，インコーポレイテッド Humanized antibodies targeting the EC1 domain of cadherin-11 and related compositions and methods
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20150064163A1 (en) 2011-09-02 2015-03-05 Lifenet Health BMP Peptides & Methods of Use
EP2685260A1 (en) 2012-07-09 2014-01-15 Ludwig-Maximilians-Universität München Direct and quantitative detection of targets in living cells
KR101609840B1 (en) * 2012-07-12 2016-04-07 한국생명공학연구원 Adsorbent columns using antibody Fcbinding peptide
RS57013B1 (en) 2012-09-11 2018-05-31 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield
KR102073748B1 (en) 2013-01-31 2020-02-05 한미약품 주식회사 Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
AR096891A1 (en) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
KR102530900B1 (en) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. Methods of treating nail and scalp psoriasis
WO2016040488A2 (en) 2014-09-10 2016-03-17 Georgetown University Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
JP7175608B2 (en) 2014-11-19 2022-11-21 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク Osteocalcin as a treatment for age-related frailty
US20180079796A1 (en) 2015-03-13 2018-03-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
AU2018364630A1 (en) 2017-11-09 2020-05-21 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269455A3 (en) * 1986-11-28 1989-09-06 Takeda Chemical Industries, Ltd. Highly purified fused protein comprising human ige fc fragment and production thereof
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
WO1991002743A1 (en) * 1989-08-23 1991-03-07 The General Hospital Corporation Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (en) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
ATE218889T1 (en) * 1990-11-09 2002-06-15 Stephen D Gillies CYTOKINE IMMUNOCONJUGATES
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210661B1 (en) 1992-03-13 2001-04-03 Aventis Pharma Deutschland Gmbh IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, and bacterial diseases and of fungal infections
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
US6328954B1 (en) 1992-08-31 2001-12-11 Aventis Pharma Deutschland Gmbh Use of the IL-4 receptor for the therapy prophylaxis and diagnosis of allergic viral parasitic and bacterial diseases and of fungal infections
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US6403077B1 (en) 1994-12-12 2002-06-11 Beth Israel Hospital Association Treatment regimes featuring an IL-10-containing chimeric polypeptide
US6770272B2 (en) 1994-12-12 2004-08-03 Beth Israel Hospital Association Treatment of diabetes
US7018626B2 (en) 1994-12-12 2006-03-28 Beth Israel Deaconess Medical Center, Inc. Chimeric IL-10
US7547436B2 (en) 1995-01-17 2009-06-16 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US7060274B2 (en) 1995-01-17 2006-06-13 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US7067129B2 (en) 1995-01-17 2006-06-27 The Brigham And Woman's Hospital, Inc. Receptor specific transepithelial transport in therapeutics
US7824675B2 (en) 1995-04-27 2010-11-02 Human Genome Sciences, Inc. Use of an antibody that binds human tumor necrosis factor receptor-like 2
US7446169B1 (en) 1995-04-27 2008-11-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
US7910321B2 (en) 1995-06-05 2011-03-22 Human Genome Sciences, Inc. Methods of determining the level of human tumor necrosis factor receptor-like 2
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6573056B2 (en) 1995-10-18 2003-06-03 Aventis Behring Gmbh Process for purifying factor VII and activated factor VII
US5968759A (en) * 1995-10-18 1999-10-19 Centeon Pharma Gmbh Method for the quantification of activated coagulation factor VII (FVIIa)
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
EP2025682A2 (en) 1996-08-16 2009-02-18 Human Genome Sciences, Inc. Human endokine alpha
EP2065396A1 (en) 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US7511017B2 (en) 1997-01-14 2009-03-31 Human Genome Sciences, Inc. Methods of treatment with TNFR5
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6902910B2 (en) 1997-01-28 2005-06-07 Human Genome Sciences, Inc. Death domain containing receptor 4
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7476384B2 (en) 1997-01-28 2009-01-13 Human Genome Sciences, Inc. Death domain containing receptor 4 antibody and methods
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6743625B2 (en) 1997-03-17 2004-06-01 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
EP1982990A1 (en) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999047538A1 (en) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US7993643B2 (en) 2000-03-02 2011-08-09 Amgen Fremont, Inc. Uses of human monoclonal antibodies against oxidized LDL receptor
EP2228389A2 (en) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
US7064189B2 (en) 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7550293B2 (en) 2002-07-19 2009-06-23 Targacept, Inc. Chimeric nicotinic receptor subunits
EP2314604A2 (en) 2002-10-15 2011-04-27 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof
EP2287314A1 (en) 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
EP2287315A1 (en) 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
EP2053125A1 (en) 2003-03-04 2009-04-29 Intercell AG Streptococcus pyogenes antigens
US7638136B2 (en) 2003-03-04 2009-12-29 Intercell Ag Streptococcus pyogene antigens
EP2311989A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
US8372411B2 (en) 2003-04-15 2013-02-12 Intercell Ag S. pneumoniae antigens
EP2311991A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
EP2298934A1 (en) 2003-04-15 2011-03-23 Intercell AG S. pneumoniae antigens
US8932830B2 (en) 2003-05-06 2015-01-13 Biogen Idec Hemophilia, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US8815250B2 (en) 2003-05-06 2014-08-26 Biogen Idec Hemophilia Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
US9636416B2 (en) 2003-05-06 2017-05-02 Bioverativ Therapeutics Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1624891A2 (en) † 2003-05-06 2006-02-15 Syntonix Pharmaceuticals, Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US7862820B2 (en) 2003-05-06 2011-01-04 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1624891B2 (en) † 2003-05-06 2013-04-10 Biogen Idec Hemophilia Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US9725496B1 (en) 2003-05-06 2017-08-08 Bioverative Therapeutics Inc. Immunoglobulin chimeric monomer-dimer hybrids
US8329182B2 (en) 2003-05-06 2012-12-11 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US11401322B2 (en) 2003-05-06 2022-08-02 Bioverativ Therapeutics Inc. Immunoglobulin chimeric monomer-dimer hybrids
US8449884B2 (en) 2003-05-06 2013-05-28 Syntonix Pharmaceuticals, Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US11168125B2 (en) 2003-05-06 2021-11-09 Bioverativ Therapeutics Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP2275435A2 (en) 2003-05-07 2011-01-19 Intercell AG Streptococcus agalactiae antigens I + II
EP2287177A2 (en) 2003-05-07 2011-02-23 Intercell AG Streptococcus agalactiae antigens I + II
EP2327720A1 (en) 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
EP2267006A1 (en) 2003-05-30 2010-12-29 Intercell AG Enterococcus antigens
US8420079B2 (en) 2004-04-22 2013-04-16 Grifols Therapeutics, Inc. Recombinantly modified plasmin
EP2246417A1 (en) 2004-04-22 2010-11-03 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US8034913B2 (en) 2004-04-22 2011-10-11 Grifols Therapeutics Inc. Recombinantly modified plasmin
EP3056571A1 (en) 2004-05-18 2016-08-17 Georg Dewald Methods and kits to detect hereditary angioedema type iii
EP2479277A2 (en) 2004-07-22 2012-07-25 Five Prime Therapeutics, Inc. Compositions and methods of use for MGD-CSF in disease treatment
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
WO2007056352A2 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
EP2055718A1 (en) 2005-11-11 2009-05-06 Ludwig-Maximilians-Universität München Targeting and tracing of antigens in living cells
EP3360965A1 (en) 2006-01-20 2018-08-15 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2007084631A2 (en) 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP2671954A2 (en) 2006-01-20 2013-12-11 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
US10233223B2 (en) 2006-01-27 2019-03-19 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US11279742B2 (en) 2006-01-27 2022-03-22 Novagen Holding Corporation Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP2671946A1 (en) 2006-06-30 2013-12-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2639301A2 (en) 2006-06-30 2013-09-18 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2287176A1 (en) 2006-09-15 2011-02-23 Intercell AG Borrelia antigens
US8303961B2 (en) 2006-09-15 2012-11-06 Intercell Ag Borrelia antigens
US8129165B2 (en) 2006-09-15 2012-03-06 Intercell Ag Borrelia antigens
EP2275434A1 (en) 2006-09-15 2011-01-19 Intercell AG Borrelia antigens
US8916159B2 (en) 2007-04-02 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US11028398B2 (en) 2007-07-26 2021-06-08 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
EP2987859A1 (en) 2007-09-27 2016-02-24 Japan Tobacco Inc Factor involved in latent infection with herpesvirus, and use thereof
WO2009041501A1 (en) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. Factor involved in latent infection with herpesvirus, and use thereof
EP3072963A1 (en) 2007-10-18 2016-09-28 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP3023502A1 (en) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
US8617863B2 (en) 2008-06-04 2013-12-31 Grifols Therapeutics Inc. Composition, method, and kit for preparing plasmin
WO2010093928A2 (en) 2009-02-12 2010-08-19 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
EP3266795A1 (en) 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Method for detecting a fig-ros fusion polynucleotide
EP2881402A1 (en) 2009-02-12 2015-06-10 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
US9206410B2 (en) 2009-03-03 2015-12-08 Grifols Therapeutics Inc. Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom
WO2010101903A2 (en) 2009-03-03 2010-09-10 Talecris Biotherapeutics, Inc. Compositions, methods and kits for preparing plasminogen; and plasmin prepared therefrom
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
EP3508497A1 (en) 2012-05-24 2019-07-10 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
WO2013174003A1 (en) 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate

Also Published As

Publication number Publication date
UY25897A1 (en) 2001-01-31
PT98113A (en) 1992-05-29
IE912256A1 (en) 1992-01-01
EP0464533A1 (en) 1992-01-08
DE59109032D1 (en) 1998-09-03
CY2151B1 (en) 2002-08-23
EP1586635A1 (en) 2005-10-19
EP0835939A2 (en) 1998-04-15
NL300009I2 (en) 2000-12-01
KR100249572B1 (en) 2000-03-15
JPH05247094A (en) 1993-09-24
DE10075010I2 (en) 2004-01-29
KR920000789A (en) 1992-01-29
HK1010216A1 (en) 1999-06-17
EP0835939B1 (en) 2005-11-09
KR100280069B1 (en) 2001-01-15
NL300009I1 (en) 2000-08-01
DE10075010I1 (en) 2003-06-12
ES2120949T3 (en) 1998-11-16
GR3027567T3 (en) 1998-11-30
HK1012015A1 (en) 1999-07-23
ATE309376T1 (en) 2005-11-15
DK0464533T3 (en) 1999-04-26
DE59109269D1 (en) 2005-12-15
ATE169030T1 (en) 1998-08-15
EP0835939B8 (en) 2006-01-11
ES2251009T3 (en) 2006-04-16
CY2000009I1 (en) 2016-10-05
AU655421B2 (en) 1994-12-22
PT98113B (en) 1998-12-31
ES2120949T4 (en) 2011-12-29
JP3768427B2 (en) 2006-04-19
EP0464533B1 (en) 1998-07-29
LU90592I2 (en) 2000-07-31
KR100280070B1 (en) 2001-01-15
EP0835939A3 (en) 1998-04-22
JP2002201200A (en) 2002-07-16
CA2045869C (en) 2009-01-27
DK0835939T3 (en) 2006-03-13
AU7935791A (en) 1992-01-02

Similar Documents

Publication Publication Date Title
CA2045869A1 (en) Fusion proteins with immunoglobulin portions, the preparation and use thereof
AU5914590A (en) Muteins of human erythropoietin, the preparation thereof and the use thereof
DE69730038D1 (en) SOLUBLE MONOVALENTS AND MULTIVALENTS MHC CLASS II FUSION PROTEINS AND THEIR USE
DE69429723T2 (en) STRESS PROTEINS AND THEIR USE
WO1995016038A3 (en) Humanized antibodies and uses thereof
EP0810285A3 (en) Mutants of human Interleukin-3
EP0754229A1 (en) Alfamin: a human serum albumin-like protein
CA2083177A1 (en) Alveolar surfactant proteins
EP1431391A3 (en) Rantes mutants and therapeutic applications thereof
NZ239183A (en) Peptides antagonistic against bombesin or like proteins and their use in the treatment of disease
IL84040A (en) Monoclonal antibodies against ifn-omega,their preparation and their use in the purification and detection of ifn-omega
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE58907373D1 (en) Modified proteins.
CA2163805A1 (en) Novel activating factor of leukocytes
ATE132877T1 (en) EMULGATOR-FREE EMULSION POLYMERS IN PHARMACEUTICAL PREPARATIONS WITH DELAYED RELEASE OF ACTIVE INGREDIENTS AND THEIR PRODUCTION
AU666482B2 (en) Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use
AU7387291A (en) Cellular binding protein having affinity for the regulatory region of the human papilloma virus type 18
DE59106997D1 (en) ANCROD SIMILAR PROTEINS, THEIR PRODUCTION AND USE.
AU619080B2 (en) 2,4-dihalogeno-6-pyridylethanolphenylisopropylamines, processes for their preparation and their use for shifting the protein-fat ratio in favour of protein
ZA915627B (en) The class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties,and vaccines containing same
CA2003360A1 (en) Human vascular permeability factor

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry